

Disclosures

Personal Commercial (23)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Alnylam Pharmaceuticals	Research/Research Grants ‡ APOLLO-B / HELIOS-B	None (\$0)	Heart Failure and Cardiomyopathies
Applied Therapeutics, Inc	Research/Research Grants ‡ Steering Committee member for ARISE-HF (AT-001 for Diabetic Cardiomyopathy)	None (\$0)	Prevention
AstraZeneca Pharmaceuticals	Research/Research Grants ‡ Site-PI for the ENDEAVOR study	None (\$0)	Heart Failure and Cardiomyopathies
Belvoir Media Group	Other - Editorship/Authorship	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
BioCardia Inc	Research/Research Grants ‡ Site PI for CardAMP Heart Failure Trial	None (\$0)	Heart Failure and Cardiomyopathies
Boston Scientific	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Bristol-Myers Squibb Company	Research/Research Grants ‡ Site-PI for Danicamtiv MYK491-006 Study	None (\$0)	Heart Failure and Cardiomyopathies
CardiaTec Biosciences	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Cardiol Therapeutics, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Cardurion Inc	Research/Research Grants ‡ Site-PI for CARDINAL-HF study	None (\$0)	Heart Failure and Cardiomyopathies
Cordio Medical Ltd	Research/Research Grants ‡ Site PI for DETECT-HF study	None (\$0)	Heart Failure and Cardiomyopathies
Genomics, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Intellia Therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Kiniksa Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Renovacor, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Salubris Biotherapeutics, Inc.	Research/Research Grants ‡ PI of JK07 Phase I Study	None (\$0)	Heart Failure and Cardiomyopathies
Second Heart Assist, Inc	Research/Research Grants ‡ PI of Second Heart Assist Device Early Feasibility Study for Cardio-Renal Syndrome	None (\$0)	Heart Failure and Cardiomyopathies
Sequana Medical, AV	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Springer Publishing	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Tenaya Therapeutics Inc	Research/Research Grants ‡ Seroprevalence study for PKP2-associated ARVC patients	None (\$0)	Heart Failure and Cardiomyopathies
WhiteSwell Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Zehna Therapeutics, LLC	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
<i>Spouse/Domestic Partner/Immediate Household Member</i>			
Cardiac Community Core Lab, LLC	Consultant Fees/Honoraria	Modest (< \$5,000)	Invasive CV Angio and Interventions

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (3)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
American Board of Internal Medicine † none	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
NIH	Research/Research Grants	Significant (>= \$5,000)	Prevention Heart Failure and Cardiomyopathies Noninvasive Imaging
Springer Nature	Other - Author/Editor	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

Clinical Trial Enroller (7)

Trial Name	Trial Sponsor	Trial Funding Source
ALN-TTR02-011 (APOLLO-B)	Anylam Pharmaceuticals	
ALN-TTRSC02-003 (HELIOS-B)	Anylam Pharmaceuticals	
ENDEAVOR	AstraZeneca Pharmaceuticals	
CardiAMP™ Cell Therapy Heart Failure Trial	BioCardia Inc	
Danicamtiv for Genetic Dilated Cardiomyopathy	Bristol-Myers Squibb Company	
HearO Trial	Cordio Medical Inc	
REALM-DCM (ARRY797-301)	Pfizer Inc	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/12/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/12/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/12/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/12/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.